Bausch Health Companies Inc
TSX:BHC
Intrinsic Value
Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. [ Read More ]
The intrinsic value of one
BHC
stock under the Base Case scenario is
91.58
CAD.
Compared to the current market price of 11.8 CAD,
Bausch Health Companies Inc
is
Undervalued by 87%.
BHC could be a value trap.A value trap occurs when a stock looks inexpensive based on fundamental analysis but fails to reach its intrinsic valuation over time, often due to underlying issues not reflected in quantitative data.
Scrutinize beyond numbers; assess long-term potential.
Bausch Health Companies Inc's market capitalization is 4.3B CAD.
BHC stock price is 11.8 CAD.
BHC stock price (11.8 CAD) is 87% less than its Intrinsic Value (91.58 CAD).
BHC stock price (11.8 CAD) is 89% less than its Relative Value (107.72 CAD). Open Relative Valuation
BHC has downside potential of 20% compared to the average analyst price target.
Open Wall St Estimates
BHC's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 10%.
BHC's Revenue has grown by 8% over the past 12 months.
BHC's Revenue has been growing by 3% per year for the last 3 years.
BHC's Revenue is forecast to grow at a rate of 4% per year over the next 3 years.
BHC's long-term liabilties (28B USD) exceed its long-term assets (27B USD).
BHC has positive three-year average ROE (Return on Equity): 12%. The company is efficient at transforming stockholders' equity into net income.
BHC's ROIC (Return on Invested Capital) has increased in the last 3 years from 4% to 10%.
BHC has positive Free Cash Flow for the last twelve months.
BHC's short-term assets (6B USD) exceed its short-term liabilties (4B USD).
BHC has positive Operating Income for the last twelve months.
BHC has a very low three-year average ROIC (Return on Invested Capital): 3%. The company is not efficient at using invested capital to generate operating income.
BHC's ROE (Return on Equity) has significantly increased in the last 3 years from -390% to 69%.
BHC has negative Net Income for the last twelve months.
BHC's ROE (Return on Equity) for the past 12 months is very high and is equal to 69%.
BHC has positive Gross Profit for the last twelve months.
BHC has positive Net Debt. This means that the company has more debt (22B USD) than cash and short-term investments (947m USD).
BHC's D/E (Debt to Equity) is very low and is equal to -21.47.
BHC's Altman Z-Score is very low and is equal to 0.11.
BHC generates enough operating income (2B USD) to cover interest payments on its debt (2B USD).
Valuation Backtest
Bausch Health Companies Inc
Run backtest to discover the historical profit from buying and selling
BHC
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Bausch Health Companies Inc
Balance Sheet Decomposition
Bausch Health Companies Inc
| Current Assets | 5.6B |
| Cash & Short-Term Investments | 947m |
| Receivables | 2B |
| Other Current Assets | 2.7B |
| Non-Current Assets | 21.8B |
| PP&E | 1.7B |
| Intangibles | 17.6B |
| Other Non-Current Assets | 2.4B |
| Current Liabilities | 4.3B |
| Accounts Payable | 719m |
| Accrued Liabilities | 3.1B |
| Other Current Liabilities | 497m |
| Non-Current Liabilities | 24.1B |
| Long-Term Debt | 21.9B |
| Other Non-Current Liabilities | 2.1B |
Earnings Waterfall
Bausch Health Companies Inc
|
Revenue
|
8.8B
USD
|
|
Cost of Revenue
|
-2.6B
USD
|
|
Gross Profit
|
6.2B
USD
|
|
Operating Expenses
|
-4.6B
USD
|
|
Operating Income
|
1.6B
USD
|
|
Other Expenses
|
-2.2B
USD
|
|
Net Income
|
-592m
USD
|
Free Cash Flow Analysis
Bausch Health Companies Inc
What is Free Cash Flow?
BHC Profitability Score
Profitability Due Diligence
Bausch Health Companies Inc's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
Score
Bausch Health Companies Inc's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
BHC Solvency Score
Solvency Due Diligence
Bausch Health Companies Inc's solvency score is 30/100. The higher the solvency score, the more solvent the company is.
Score
Bausch Health Companies Inc's solvency score is 30/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BHC Price Targets Summary
Bausch Health Companies Inc
According to Wall Street analysts, the average 1-year price target for
BHC
is 9.44 CAD
with a low forecast of 9.09 CAD and a high forecast of 9.98 CAD.
Shareholder Return
BHC Price
Bausch Health Companies Inc
| Average Annual Return | -14.06% |
| Standard Deviation of Annual Returns | 48.37% |
| Max Drawdown | -87% |
| Market Capitalization | 4.3B CAD |
| Shares Outstanding | 365 412 000 |
| Percentage of Shares Shorted | 0.62% |
BHC News
Last Important Events
Bausch Health Companies Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Bausch Health Companies Inc
Company Profile
Bausch Health Companies Inc
Country
Industry
Market Cap
Dividend Yield
Description
Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. The company is headquartered in Laval, Quebec and currently employs 19,600 full-time employees. The firm is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in over 100 countries. Its segments include Bausch + Lomb, Salix, Ortho Dermatologics, International Rx and Diversified Products. The Bausch + Lomb segment consists of sales in the United States of Bausch + Lomb Vision Care, Consumer, Surgical and Ophthalmology Rx products. The Salix segment consists of sales in the United States of gastroenterology (GI) products. The Ortho Dermatologics segment consists of sales in the United States of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices.
Contact
IPO
Employees
Officers
The intrinsic value of one
BHC
stock under the Base Case scenario is
91.58
CAD.
Compared to the current market price of 11.8 CAD,
Bausch Health Companies Inc
is
Undervalued by 87%.
You don't have any saved screeners yet
